9/4/2024

Bevacizumab-bvzr Injection

Products Affected - Description

- Zirabev injection, Pfizer, 25 mg/mL, 16 mL vial, 1 count, NDC 00069-0342-01
- Zirabev injection, Pfizer, 25 mg/mL, 4 mL vial, 1 count, NDC 00069-0315-01

Reason for the Shortage

- Pfizer has Zirabev on shortage due to manufacturing delays.

Available Products

- There is insufficient supply for usual ordering

Estimated Resupply Dates

- Pfizer has Zirabev 25 mg/mL 4 mL vials on allocation. The 16 mL vials are expected to be depleted in September and the company estimates a release date of late-November 2024. Both presentations are on a Medical Reserve for emergency requests.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.